



# **Borders Formulary Committee**

## **Annual Report**

**April 2017 – March 2018**

## CONTENTS

1	NHS Borders Formulary Committee Purpose	Page 3
2	BFC Membership	Page 3
3	Business	Page 3
4	BFC – Formulary Updates	Page 4
5	BFC – Applications and Decisions	Page 5-7
6	BFC Meeting Attendees 2017/18	Page 8

## **1. Purpose**

Borders Formulary Committee is a sub committee of the Area Drug and Therapeutics Committee and is accountable to the Strategy Group.

Its purpose is to provide NHS Borders Board with the assurance that mechanisms are in place and effective across NHS Borders to manage requests to support cost-effective, evidence based, prescribing of medicines.

## **2. BFC Membership**

During the financial year ending 31 March 2018 membership of NHS Borders Formulary Committee comprised:

Mrs Alison Wilson (Chair) – Director of Pharmacy  
Ms Liz Leitch – Formulary Pharmacist  
Mrs Catherine Scott – Senior Clinical and Development Pharmacist  
Mr Keith Maclure – Prescribing Support Pharmacist  
Dr Paul Neary – Consultant Cardiologist  
Dr Lindsey Burton – Medical Registrar replaced in August 2017 by  
Dr Joanne Graham – Medical Registrar  
Dr Elliot Longworth - GP  
Dr Paul Marynicz – GP replaced in August 2017 by  
Dr Nicola Henderson - GP

Minute Secretary  
Kate Warner – PA to Director of Pharmacy

## **3 Business**

Core agenda items on the Committee's agenda include:-

- Committee members review New Medicine Applications for drugs from NHS Borders clinicians to be included in the formulary.
- Committee members note medicines reviewed by the Scottish Medicine Consortium (SMC), and guidance published by NICE, SIGN and NHS Quality Improvement Scotland (QIS).
- Borders Joint Formulary Updates – committee members review and approve changes to formulary sections. The committee supports development of guidelines & protocols relating to safe use of medicines.
- Patient Safety.

## 4 BFC – Formulary, Guideline and Protocol Updates

<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 12<sup>th</sup> APRIL 2017</b>
Pharmacists Formulary for Minor Ailments Scheme; Vitamin D; Smoking Cessation
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 12<sup>th</sup> APRIL 2017</b>
NHS Borders New Medicines Decisions update to template; NHS Borders Guidance for Parkinson's Disease; INR - Therapeutic Range; Update on DOAC consensus statement; Lidocaine Patches.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 14<sup>th</sup> JUNE 2017</b>
Abbreviated Borders Joint Formulary booklet.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 14<sup>th</sup> JUNE 2017</b>
BFC Annual Report 2016/17; New Medicines Decisions website template; New Medicines Application Form and Procedure update; Guidance for Cost Sensitive HIV Therapy Prescribing in NHS Scotland; Single National Formulary event; New SMC website NICE multiple technology appraisals; Lidocaine Patches; Aspirin and Cardiology patients.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 9<sup>th</sup> AUGUST 2017</b>
Specialist initiated drugs for Chronic Plaque Psoriasis; Disorders of Bone Metabolism; Edoxaban (Lixiana); Lidocaine Plaster Request; Vitamin D.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 9<sup>th</sup> AUGUST 2017</b>
Changes to Anti-coagulant Policies - Dalteparin; Coaguchek Test; SCAN Protocol.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 11<sup>th</sup> OCTOBER 2017</b>
No formulary updates.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 11<sup>th</sup> OCTOBER 2017</b>
Development of a National Recommendation for ADTC ratification on preferred DOAC for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 13<sup>th</sup> DECEMBER 2017</b>
Drugs Used in Psychoses and Related Disorders; Gluten Free Formulary update.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 13<sup>th</sup> DECEMBER 2017</b>
Medication Algorithm for Secondary Prevention after TIA/Ischaemic Stroke; Napp product: Inhaled Intranasal Naloxone (Nyxoid); Drugs which should not be used routinely in Primary Care.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 14<sup>th</sup> FEBRUARY 2018</b>
Pembrolizumab; Glucodrate removal from Formulary.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 14<sup>th</sup> FEBRUARY 2018</b>
Borders Joint Formulary Abbreviated booklet update; Non Formulary Request form update; Single National Formulary update; MRHA warning for Esmya.

## 5 BFC – Applications and Decisions

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 12 <sup>th</sup> APRIL 2017		
NMA	Indication	BFC Decision
Insulin aspart (Fiasp)	Treatment of diabetes mellitus in adults.	Category C
Omnican Lance Soft Lancets	Used to get the blood sample to test blood glucose in diabetic patients.	Category A
Unilet Eco Lancets	Used to get the blood sample to test blood glucose in diabetic patients	Category A
Aztreonam (Azactam)	Alternative to carbapenems in treatment of severe infection caused by susceptible Gram negative bacteria on the advice of Consultant Microbiologist.	Category B
Emtricitabine/tenofovir disoproxil (Truvada)	In combination with safer sex practices for pre-exposure prophylaxis to reduce risk of sexually acquired HIV-1 infection in adults at high risk.	Category B
Glucodrate	Dietary management of short bowel-associated intestinal failure and intestinal insufficiency.	Category B
Ixekizumab 80mg solution for injection (Taltz®)	Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Category B
Nepafenac 3mg/ml eye drops (Nevenac)	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 14 <sup>th</sup> JUNE 2017		
NMA	Indication	BFC Decision
No applications at this meeting.		
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 9 <sup>th</sup> AUGUST 2017		
NMA	Indication	BFC Decision
Ustekinumab (Stelara)	Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies	Category B
Budesonide/for moterol (Symbicort SMART)	The regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting β2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" short-acting β2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. This advice relates to the extension of the license for Symbicort maintenance and reliever therapy (SMART®) to adolescents aged 12 to <18 years. SMC has previously accepted Symbicort maintenance and reliever therapy (SMART®) in adults.	Category C
Obeticholic Acid (Ocaliva)	Primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid	Category B
Ciprofloxacin + Dexamethasone ear drops (Cilodex)	Treatment of following infections in adults and children: Acute otitis media in patients with tympanostomy tubes (AOMT); acute otitis externa.	Category B

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 11 <sup>th</sup> OCTOBER 2017		
NMA	Indication	BFC Decision
Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trimbow)	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. SMC restriction: severe COPD (forced expiratory volume in one second less than 50% predicted normal). Trimbow costs less than inhalers containing beclometasone dipropionate / formoterol fumarate 100 micrograms/ 6 micrograms and glycopyrronium 44.	Category C
Stiripentol	In conjunction with clobazam and valporate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet's Syndrome) whose seizures are not adequately controlled with clobazam and valporate	Category C
Edoxaban (Lixiana)	Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAf) with one or more risk factors, such as congestive heart failure, hypertension, age ≥65 years, diabetes mellitus prior to stroke or transient ischaemic attack (TIA). Replacing Rivaroxaban as a second choice NOAC for this indication.	Category A
Baricitinib	Moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). May be used as monotherapy or in combination with methotrexate.	Category B
Mydrane	Indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia during the surgical procedure.	Category B
Sofosbuvir velpatasvir (Epclusa)	Treatment of chronic hepatitis C virus (HCV) infection in adults; Generic Name: Sofosbuvir-Velpatasvir.	Category B
SMA Pro Breast Milk Fortifier	Infants <34 weeks gestation and <1500g birthweight should be considered for fortification. Some preterm infants with a birthweight of >1500g and <2000g may also benefit from breast milk fortifier	Category B
Methylphenidate XL (Xaggitin XL)	ADHD	Category D
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 13 <sup>th</sup> DECEMBER 2017		
NMA	Indication	BFC Decision
Desmopressin (Noqdirna)	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults	Category C
Glecaprevir/Pibrentasvir (Maviret)	Treatment of chronic hepatitis C virus (HCV) infection in adults	Category B
Pegvisomant (Somavert)	Treatment of adult patients with acromegaly who have had inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 (insulin-like growth factor 1) concentrations or was not tolerated	Category B
Lift Plus Citrus 360	Adhesive remover spray to remove stoma pouch from skin	Category A
Freestyle Libre Sensors	Measures glucose levels in interstitial fluid in people aged 4 and above with DM, including pregnant women	Category C (subsequent use only after feedback and GP guidance)

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 14 <sup>th</sup> FEBRUARY 2018		
NMA		BFC Decision
Indocyanine green dye	To enhance bowel tissue imaging during surgery for colorectal cancer.	Category B up to 25 patients
Levonorgestrel (Kyleena)	Contraception	Category D
Fluticasone Furoate (Trelegy Ellipta)	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting $\beta_2$ -agonist.	Category C
Sildenafil	Severe Raynaud's related to underlying connective tissue disease (usually systemic sclerosis, but occasionally in SLE or other connective tissue diseases), unresponsive to standard agents such as nifedipine at maximal tolerated dose, resulting in digital ulceration or critical ischaemia, using the drug as a daily therapy.	Category C
Tofacitinib citrate (Xeljanz)	In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.	Category B
Belimumab (Benlysta)	Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard Therapy	Category B

#### New Medicine Product/Device Endorsement Categories

<b>A</b>	Approved for general use - hospital and general practice
<b>B</b>	Approved for specialist use only
<b>C</b>	Approved for consultant initiation, with ongoing prescribing in general practice
<b>D</b>	Approved for shared care between hospital and general practice. Shared care protocol to be developed. (Information included here)
<b>E</b>	Not approved (reason given)
<b>F</b>	No decision – further information required (listed here)

## 6 BFC Meeting Attendees 2017/18

Name	Meeting Dates					
	12.04.17	14.06.17	09.08.17	11.10.17	13.12.17	14.02.18
Mrs Alison Wilson	✓	✓	✓	✓	✓	✓
Ms Liz Leitch	✓	✓	✓	✓	✓	✓
Mrs Catherine Scott	✓			✓	✓	✓
Mr Keith Maclure	✓	✓	✓	✓		✓
Dr Paul Neary		✓		✓	✓	✓
Dr Lindsey Burton	✓					
Dr Joanne Graham				✓		✓
Dr Elliot Longworth			✓		✓	✓
Dr Paul Marynicz	✓	✓				✓
Dr Nicola Henderson				✓		
Kate Warner (Minute)	✓	✓	✓	✓	✓	✓
Guests						
David Romanes	✓					
Fiona Fealy		✓				
Graeme Sutherland			✓			
Kirsty Lamb			✓			
Gillian Elkin					✓	
Dr Karol Pal						✓

### Declarations of Interest

- 14.06.17 Dr P Neary was involved in advisory board for manufacturer of oral potassium binder and the heart failure iron injections.
- 11.10.17 Dr P Neary received sponsorship earlier this year from Daiichi Sankyo, manufacturers of Enoxaban, to attend conference.